|View printer-friendly version|
Third Quarter and Recent Corporate Accomplishments
Asterias Biotherapeutics, Inc., completed its acquisition of Geron Corporation’s stem cell assets, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. The contributed assets include four cell lines, each with animal proof of concept, from which multiple therapeutic product candidates may be selected by Asterias for development in the fields of neurology, oncology, orthopedics, and cardiology.
BioTimeinitiated a clinical safety study of Renevia™ at The Stem Center in Palma de Mallorca, Spain, a patient therapy center, laboratory, and research facility located within the hospital Clinica USP Palmaplanas in Palma. Examinations of the subjects after they received Renevia™ injections have shown that Renevia™ was well-tolerated by all subjects with no serious adverse events or subject withdrawals. All enrolled subjects were released from the study after the final four-week follow-up appointment. The clinical report will be written pending a final check of the data.
BioTimesubsidiary OncoCyte Corporationentered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Instituteto collaboratively develop lung cancer diagnostic products. OncoCyte scientists will analyze blood samples obtained from patients in a Wistar clinical study to determine levels of tumor-associated proteins found in the blood samples. The data obtained from the samples received from Wistar's ongoing multi-center study may allow OncoCyte to more rapidly develop a diagnostic test for lung cancer to be marketed in the U.S. and other countries.
Asterias entered into a Non-Exclusive License Agreement with the
Wisconsin Alumni Research Foundation(“WARF”) under which Asterias was granted a worldwide non-exclusive license to use certain WARF patents and WARF-owned embryonic stem cell lines in the development and commercialization of therapeutic, diagnostic and research products.
BioTimecommenced the development of two new products based on its HyStem® technology platform. The new products are unique formulations utilizing some of the same cGMP components used in Renevia™. The first of these new products is ReGlyde™, a cross-linked thiol-modified hyaluronan hydrogel for the management and protection of tendon injuries following surgical repair of the digital flexor or extensor tendons of the hand. The second new product, Premvia™, is a HyStem® hydrogel formulation of cross-linked thiol-modified hyaluronan and thiol-modified gelatin for the management of wounds including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns.
BioTimeentered into an Exclusive Sublicense Agreement with Jade Therapeutics, Inc.permitting Jade to use BioTime’s HyStem® hydrogel technology as an ophthalmic sustained-release drug delivery platform for the delivery of therapeutic molecules to the human eye. Excluded from the licensed field of use is the use of the HyStem® technology for use in making punctal plugs, for diagnostic and research reagents, for the delivery of cells with or without any molecules necessary for the therapeutic benefit of those cells, and for non-human applications.
BioTimeconsolidated its research products business into a new ESI BIOdivision, which will now be BioTime’s primary developer, manufacturer and distributor of its growing portfolio of stem cell based research products. This new division includes BioTime’s Singaporesubsidiary ES Cell International Pte Ltd.This consolidation will allow for a more focused approach on the development, manufacture and marketing of BioTime’s research products portfolio. Jeffrey Janus, BioTime’s Vice President of Sales and Marketing, will manage ESI BIOand will take on the added role as the Chief Executive Officer of ES Cell InternationalPte Ltd.
BioTimeappointed Lesley Stolz, Ph.D. as Executive Vice President, Corporate Development. Dr. Stolz will have primary responsibility for interactions with both investors and corporate partners. Additionally, she will focus on identifying and implementing strategic initiatives for BioTimeand its subsidiaries. Dr. Stolz has more than 18 years of life science industry experience in corporate and business development.
Net loss attributable to
Total net revenue on a consolidated basis was
Total operating expenses for the third quarter of 2013 were
Total operating expenses for the first nine months of 2013 were
The increase in operating expenses of
Net cash used in operating activities was
Net cash provided by financing activities was
Cash and cash equivalents, on a consolidated basis, totaled
Asterias Biotherapeutics, Inc.is a new subsidiary which has acquired the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine.
OncoCyte Corporationis developing products and technologies to diagnose and treat cancer.
Cell Cure Neurosciences Ltd.(“Cell Cure Neurosciences”) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.
LifeMap Sciences, Inc.(“LifeMap Sciences”) markets, sells and distributes GeneCards®, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery™ database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.
ES Cell International Pte Ltd., a Singaporeprivate limited company, developed hES cell lines and may market those cell lines and other BioTimeresearch products in over-seas markets as part of BioTime’s ESI BIO Division.
OrthoCyte Corporationis developing therapies to treat orthopedic disorders, diseases and injuries.
ReCyte Therapeutics, Inc.is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for
To receive ongoing
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|September 30, 2013||December 31,|
|Cash and cash equivalents||$||6,717,343||$||4,349,967|
|Prepaid expenses and other current assets||1,900,913||2,774,196|
|Total current assets||8,679,388||7,179,479|
|Deferred license and consulting fees||583,208||669,326|
|Intangible assets, net||18,559,074||20,486,792|
|LIABILITIES AND EQUITY|
|Accounts payable and accrued liabilities||$||4,201,098||$||3,989,962|
|Deferred grant income||47,349||
|Deferred license and subscription revenue, current portion||349,849||400,870|
|Total current liabilities||4,598,296||4,390,832|
|Deferred license revenue, net of current portion||644,273||768,678|
|Deferred rent, net of current portion||42,095||57,214|
|Other long term liabilities||200,582||237,496|
|Total long-term liabilities||886,950||1,063,388|
|Commitments and contingencies|
|Preferred Shares, no par value, authorized 2,000,000 and 1,000,000 shares respectively, as of September 30, 2013 and December 31, 2012; none issued||
|Common shares, no par value, authorized 125,000,000 and 75,000,000 shares respectively, as of September 30, 2013 and December 31, 2012; 57,938,220 issued and 55,622,934 outstanding at September 30, 2013 and 51,183,318 issued and 49,383,209 outstanding as of December 31, 2012||149,008,287||119,821,243|
|Accumulated other comprehensive income/(loss)||124,740||(59,570)|
|Treasury stock at cost: 2,315,286 and 1,800,109 shares at September 30, 2013 and at December 31, 2012, respectively.||(10,120,653)||(8,375,397)|
|Total shareholders' equity||12,940,113||9,584,536|
|TOTAL LIABILITIES AND EQUITY||$||30,853,664||29,748,593|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS|
|Three Months Ended||Nine Months Ended|
|September 30, 2013||September 30, 2012||September 30, 2013||September 30, 2012|
|Royalties from product sales||80,592||133,946||291,505||407,803|
|Sale of research products||90,272||90,342||214,277||217,380|
|Cost of Sales||(206,678||)||(169,734||)||(570,237||)||(273,916||)|
|Total revenues, net||507,384||833,817||1,971,614||2,418,874|
|Research and development||(6,441,462||)||(4,545,470||)||(17,389,409||)||(13,323,410||)|
|General and administrative||(4,267,875||)||(2,234,905||)||(11,273,948||)||(7,037,807||)|
|Loss from operations||(10,201,953||)||(5,946,558||)||(26,691,743||)||(17,942,343||)|
|Interest income, net||509||5,624||2,033||17,321|
|Gain/(Loss) on sale of fixed assets||5,830||(1,451||)||5,120||(4,997||)|
|Other income/(expense), net||(60,704||)||18,766||(169,512||)||(223,899||)|
|Total other income/(expenses), net||(54,365||)||22,939||(162,359||)||(211,575||)|
|Less: Net loss attributable to the noncontrolling interest||1,253,150||965,605||2,583,581||2,763,169|
|NET LOSS ATTRIBUTABLE TO BIOTIME, INC. (1)||$||(9,003,168||)||$||(4,958,014||)||$||(24,270,521||)||$||(15,390,749||)|
|Foreign currency translation gain/(loss)||7,016||(15,777||)||184,310||(74,635||)|
|COMPREHENSIVE NET LOSS (2)||$||(8,996,152||)||$||(4,973,791||)||$||(24,086,211||)||$||(15,465,384||)|
|BASIC AND DILUTED LOSS PER COMMON SHARE (1)||$||(0.16||)||$||(0.10||)||$||(0.45||)||$||(0.31||)|
|WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED||55,621,564||49,291,177||53,545,834||49,196,804|
|(1) Basic and diluted loss per common share is calculated using "Net loss attributable to BioTime, Inc."|
|(2) Comprehensive net loss includes foreign currency translation gain of $7,016 and $184,310 for the three and nine months ended September 30, 2013, respectively and translation loss of $15,777 and $74,635 for the same periods in the prior year, respectively arise entirely from the translation of foreign subsidiary financial information for consolidation purposes and therefore not used in the calculation of basic and diluted loss per common share.|
Lesley Stolz, 510-521-3390 ext. 367
Executive Vice President Corporate Development
Judith Segall, 510-521-3390 ext. 301
Robert Peabody, 510-521-3390 ext. 302
Senior Vice President & CFO